AQP4 and Parkinson disease: However, the application of pharmacological AQP4 modulators may not be beneficial in the case of PD due to insufficient druggability, probable side effects owing to the region-specific distribution of AQP4, its multifactorial implication in different pathways, and the impact of co-pathologies [107,108,109,185,189].